Emalex Biosciences (USA) received a US Patent and Trademark Office grant covering an orally disintegrating tablet formulation of ecopipam, a selective dopamine D1/D5 receptor antagonist in development for Tourette syndrome. The formulation patent protects a rapidly dispersing oral dosage form of the active compound, extending the intellectual property position of an asset that already holds US FDA Orphan Drug and Fast Track designations for pediatric Tourette syndrome patients. This formulation-level protection matters scientifically because the ODT delivery format addresses a distinct pharmaceutical challenge: providing a dosage form suited to a pediatric population in which swallowing compliance and palatability can affect adherence to chronic therapy.
Ecopipam’s mechanism operates through selective blockade of the D1 receptor family, which includes the D1 and D5 subtypes. Tourette syndrome has been hypothesized to involve abnormal dopaminergic signaling within cortico-striato-thalamo-cortical circuits, where dysregulated receptor activity is associated with the repetitive motor and vocal tics that define the condition. The D1-pathway rationale is supported by completed clinical work, including a Phase II randomized, placebo-controlled crossover study in children (NCT02102698) and a Phase II open-label extension (NCT04114539), both of which have concluded. Emalex announced in February 2025 that a Phase III maintenance-of-effect trial for ecopipam in Tourette syndrome met the primary and secondary endpoints, and in October 2025 the company said it planned an NDA submission in late 2025.
The ODT formulation patent covers the composition of a tablet designed to disintegrate without water, a delivery attribute with practical relevance in pediatric CNS indications. Emalex Biosciences states that planned development work for the ODT will include process development, scale-up, cGMP manufacturing, stability studies, and a first-in-human pharmacokinetic study targeted for late 2026 or early 2027. That study will assess the ODT against the existing immediate-release tablet, alongside tolerability and palatability evaluations. Specific clinical results for this ODT cohort remain undisclosed.
Concurrent with the patent announcement, Emalex Biosciences disclosed that its Expanded Access Program for ecopipam is enrolling up to 200 patients at US sites. The program provides access to ecopipam outside of clinical trials for patients who have exhausted approved treatment options, including aripiprazole, haloperidol, pimozide, and other D2 receptor antagonists, and who have experienced treatment failure, tolerability concerns, or access barriers.
Context and competitive landscape
The mechanistic positioning of ecopipam within the Tourette syndrome treatment field is defined by its D1 receptor selectivity, which separates it from all currently approved pharmacological options. Aripiprazole (Otsuka Pharmaceutical, Japan), marketed in the US as Abilify and approved by US FDA for Tourette syndrome, acts as a partial agonist at D2 and D3 receptors and as a partial agonist at serotonin 5-HT1A receptors. Haloperidol (various generic manufacturers), one of the oldest approved agents for tic suppression, is a D2-family antagonist with a tolerability profile that limits use in pediatric populations. Pimozide (various manufacturers), also US FDA-approved for Tourette syndrome, blocks D2 receptors and carries a black box warning related to cardiac conduction effects. Each of these agents operates through D2-pathway modulation, a mechanistic class that ecopipam’s D1-directed approach explicitly does not replicate.
Within the investigational dopaminergic space, valbenazine (Neurocrine Biosciences, USA), a vesicular monoamine transporter 2 inhibitor approved for tardive dyskinesia, has been evaluated in Tourette syndrome through Phase II and Phase III programs, representing a functional competitor for the same patient population through a distinct mechanism of depleting presynaptic dopamine stores rather than blocking postsynaptic receptors. Deutetrabenazine (Teva Pharmaceutical Industries, Israel), another VMAT2 inhibitor approved for tardive dyskinesia and Huntington’s disease chorea, has also been studied in tic disorders. Neither asset targets D1 receptors directly. The Emalex Biosciences patent on the ODT ecopipam formulation therefore consolidates intellectual property around a delivery system for the only clinical-stage D1 antagonist in the Tourette syndrome field, layered on top of existing Orphan Drug exclusivity that would apply upon any future approval.